Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 + Bevacizumab in Metastatic Refractory Choriocarcinoma
NCT02396511Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carotuximab in choriocarcinoma, sponsored by TRACON Pharmaceuticals, Inc. Primary endpoints: Progression Free Survival at 35 months and Objective Response Rate at 35 months. Started Jan 2015; status: completed.
02
Drugs
carotuximab
03
Conditions
choriocarcinoma
Beyond the preview
Go deeper on NCT02396511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396511.